Comparing Collegium Pharmaceutical (NASDAQ:COLL) & MediciNova (NASDAQ:MNOV)

MediciNova (NASDAQ:MNOV – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares MediciNova and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediciNova -1,126.60% -26.47% -24.24%
Collegium Pharmaceutical 4.68% 85.14% 13.80%

Volatility and Risk

MediciNova has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Earnings and Valuation

This table compares MediciNova and Collegium Pharmaceutical”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediciNova $920,481.00 72.46 -$12.00 million ($0.21) -6.45
Collegium Pharmaceutical $780.57 million 1.00 $62.87 million $1.00 25.23

Collegium Pharmaceutical has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for MediciNova and Collegium Pharmaceutical, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediciNova 1 1 4 1 2.71
Collegium Pharmaceutical 0 2 7 1 2.90

MediciNova presently has a consensus price target of $7.75, indicating a potential upside of 471.96%. Collegium Pharmaceutical has a consensus price target of $44.00, indicating a potential upside of 74.42%. Given MediciNova’s higher possible upside, analysts clearly believe MediciNova is more favorable than Collegium Pharmaceutical.

Institutional & Insider Ownership

9.9% of MediciNova shares are owned by institutional investors. 14.0% of MediciNova shares are owned by company insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Collegium Pharmaceutical beats MediciNova on 10 of the 14 factors compared between the two stocks.

About MediciNova

(Get Free Report)

MediciNova is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries. Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.